In thinking through the Amarin v. Hikma case, am I correct in thinking that it might be in Hikma's best interest to settle with Amarin, rather than risk losing at trial and establishing another Hatch-Waxman precedent? (monetary damages aside)
I don't think IPE can be all that profitable for them, and seems that it could get much worse (with potential tariffs, and the loss of some insurance coverage). So it seems that settling would be in their best interest, especially if they could get Amarin to agree at the right moment.
If they are truly concerned about the fate of skinny labels, it seems that a negative judgment here could impact them beyond just their IPE product.
Does that line of thinking make sense?
And if so, would it make sense for Amarin to agree to a settlement? And if so, how would that impact the other generics?
Market Data 
Markets 
